Global Endothelin Antagonists Therapeutics Market Growth 2026-2032
The global Endothelin Antagonists Therapeutics market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
Endothelin are the type of therapeutics that inhibits the action of endothelin and is thus effective for treating pulmonary arterial hypertension. This receptor, which plays a major role in regulating vascular tone, is found between the lumen and underlying media of the pulmonary vasculature. For patients suffering from the pulmonary hypertension, the body secrete high amount of endothelin that causes the blood vessels to be constricted and increase in the BP in the pulmonary arteries.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the ?Endothelin Antagonists Therapeutics Industry Forecast? looks at past sales and reviews total world Endothelin Antagonists Therapeutics sales in 2025, providing a comprehensive analysis by region and market sector of projected Endothelin Antagonists Therapeutics sales for 2026 through 2032. With Endothelin Antagonists Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Endothelin Antagonists Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global Endothelin Antagonists Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Endothelin Antagonists Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Endothelin Antagonists Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Endothelin Antagonists Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Endothelin Antagonists Therapeutics.
This report presents a comprehensive overview, market shares, and growth opportunities of Endothelin Antagonists Therapeutics market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Endothelin are the type of therapeutics that inhibits the action of endothelin and is thus effective for treating pulmonary arterial hypertension. This receptor, which plays a major role in regulating vascular tone, is found between the lumen and underlying media of the pulmonary vasculature. For patients suffering from the pulmonary hypertension, the body secrete high amount of endothelin that causes the blood vessels to be constricted and increase in the BP in the pulmonary arteries.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the ?Endothelin Antagonists Therapeutics Industry Forecast? looks at past sales and reviews total world Endothelin Antagonists Therapeutics sales in 2025, providing a comprehensive analysis by region and market sector of projected Endothelin Antagonists Therapeutics sales for 2026 through 2032. With Endothelin Antagonists Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Endothelin Antagonists Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global Endothelin Antagonists Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Endothelin Antagonists Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Endothelin Antagonists Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Endothelin Antagonists Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Endothelin Antagonists Therapeutics.
This report presents a comprehensive overview, market shares, and growth opportunities of Endothelin Antagonists Therapeutics market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Oral
- Parenteral
- Cardiovascular Diseases
- Scleroderma
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Gilead Sciences, Inc
- Sun Pharmaceutical Industries Ltd
- Lupin
- Zydus Group
- Endo International plc
- Mylan NV
- Teva Pharmaceutical Industries Ltd
- Sigmapharm Laboratories , LLC
- Alembic Pharmaceuticals Limited
- Hikma Pharmaceuticals PLC
- Amneal Pharmaceuticals LLC
- AstraZeneca
- Johnsons & Johnsons Private limited
- GSK Plc
- What is the 10-year outlook for the global Endothelin Antagonists Therapeutics market?
- What factors are driving Endothelin Antagonists Therapeutics market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Endothelin Antagonists Therapeutics market opportunities vary by end market size?
- How does Endothelin Antagonists Therapeutics break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Endothelin Antagonists Therapeutics Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Endothelin Antagonists Therapeutics by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Endothelin Antagonists Therapeutics by Country/Region, 2021, 2025 & 2032
2.2 Endothelin Antagonists Therapeutics Segment by Type
2.2.1 Oral
2.2.2 Parenteral
2.2.3 Endothelin Antagonists Therapeutics Sales by Type
2.2.3.1 Global Endothelin Antagonists Therapeutics Sales Market Share by Type (2021-2026)
2.2.3.2 Global Endothelin Antagonists Therapeutics Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Endothelin Antagonists Therapeutics Sale Price by Type (2021-2026)
2.3 Endothelin Antagonists Therapeutics Segment by Application
2.3.1 Cardiovascular Diseases
2.3.2 Scleroderma
2.3.3 Other
2.3.4 Endothelin Antagonists Therapeutics Sales by Application
2.3.4.1 Global Endothelin Antagonists Therapeutics Sale Market Share by Application (2021-2026)
2.3.4.2 Global Endothelin Antagonists Therapeutics Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Endothelin Antagonists Therapeutics Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Endothelin Antagonists Therapeutics Breakdown Data by Company
3.1.1 Global Endothelin Antagonists Therapeutics Annual Sales by Company (2021-2026)
3.1.2 Global Endothelin Antagonists Therapeutics Sales Market Share by Company (2021-2026)
3.2 Global Endothelin Antagonists Therapeutics Annual Revenue by Company (2021-2026)
3.2.1 Global Endothelin Antagonists Therapeutics Revenue by Company (2021-2026)
3.2.2 Global Endothelin Antagonists Therapeutics Revenue Market Share by Company (2021-2026)
3.3 Global Endothelin Antagonists Therapeutics Sale Price by Company
3.4 Key Manufacturers Endothelin Antagonists Therapeutics Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Endothelin Antagonists Therapeutics Product Location Distribution
3.4.2 Players Endothelin Antagonists Therapeutics Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR ENDOTHELIN ANTAGONISTS THERAPEUTICS BY GEOGRAPHIC REGION
4.1 World Historic Endothelin Antagonists Therapeutics Market Size by Geographic Region (2021-2026)
4.1.1 Global Endothelin Antagonists Therapeutics Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Endothelin Antagonists Therapeutics Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Endothelin Antagonists Therapeutics Market Size by Country/Region (2021-2026)
4.2.1 Global Endothelin Antagonists Therapeutics Annual Sales by Country/Region (2021-2026)
4.2.2 Global Endothelin Antagonists Therapeutics Annual Revenue by Country/Region (2021-2026)
4.3 Americas Endothelin Antagonists Therapeutics Sales Growth
4.4 APAC Endothelin Antagonists Therapeutics Sales Growth
4.5 Europe Endothelin Antagonists Therapeutics Sales Growth
4.6 Middle East & Africa Endothelin Antagonists Therapeutics Sales Growth
5 AMERICAS
5.1 Americas Endothelin Antagonists Therapeutics Sales by Country
5.1.1 Americas Endothelin Antagonists Therapeutics Sales by Country (2021-2026)
5.1.2 Americas Endothelin Antagonists Therapeutics Revenue by Country (2021-2026)
5.2 Americas Endothelin Antagonists Therapeutics Sales by Type (2021-2026)
5.3 Americas Endothelin Antagonists Therapeutics Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Endothelin Antagonists Therapeutics Sales by Region
6.1.1 APAC Endothelin Antagonists Therapeutics Sales by Region (2021-2026)
6.1.2 APAC Endothelin Antagonists Therapeutics Revenue by Region (2021-2026)
6.2 APAC Endothelin Antagonists Therapeutics Sales by Type (2021-2026)
6.3 APAC Endothelin Antagonists Therapeutics Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Endothelin Antagonists Therapeutics by Country
7.1.1 Europe Endothelin Antagonists Therapeutics Sales by Country (2021-2026)
7.1.2 Europe Endothelin Antagonists Therapeutics Revenue by Country (2021-2026)
7.2 Europe Endothelin Antagonists Therapeutics Sales by Type (2021-2026)
7.3 Europe Endothelin Antagonists Therapeutics Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Endothelin Antagonists Therapeutics by Country
8.1.1 Middle East & Africa Endothelin Antagonists Therapeutics Sales by Country (2021-2026)
8.1.2 Middle East & Africa Endothelin Antagonists Therapeutics Revenue by Country (2021-2026)
8.2 Middle East & Africa Endothelin Antagonists Therapeutics Sales by Type (2021-2026)
8.3 Middle East & Africa Endothelin Antagonists Therapeutics Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Endothelin Antagonists Therapeutics
10.3 Manufacturing Process Analysis of Endothelin Antagonists Therapeutics
10.4 Industry Chain Structure of Endothelin Antagonists Therapeutics
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Endothelin Antagonists Therapeutics Distributors
11.3 Endothelin Antagonists Therapeutics Customer
12 WORLD FORECAST REVIEW FOR ENDOTHELIN ANTAGONISTS THERAPEUTICS BY GEOGRAPHIC REGION
12.1 Global Endothelin Antagonists Therapeutics Market Size Forecast by Region
12.1.1 Global Endothelin Antagonists Therapeutics Forecast by Region (2027-2032)
12.1.2 Global Endothelin Antagonists Therapeutics Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Endothelin Antagonists Therapeutics Forecast by Type (2027-2032)
12.7 Global Endothelin Antagonists Therapeutics Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Gilead Sciences, Inc
13.1.1 Gilead Sciences, Inc Company Information
13.1.2 Gilead Sciences, Inc Endothelin Antagonists Therapeutics Product Portfolios and Specifications
13.1.3 Gilead Sciences, Inc Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Gilead Sciences, Inc Main Business Overview
13.1.5 Gilead Sciences, Inc Latest Developments
13.2 Sun Pharmaceutical Industries Ltd
13.2.1 Sun Pharmaceutical Industries Ltd Company Information
13.2.2 Sun Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Product Portfolios and Specifications
13.2.3 Sun Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Sun Pharmaceutical Industries Ltd Main Business Overview
13.2.5 Sun Pharmaceutical Industries Ltd Latest Developments
13.3 Lupin
13.3.1 Lupin Company Information
13.3.2 Lupin Endothelin Antagonists Therapeutics Product Portfolios and Specifications
13.3.3 Lupin Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Lupin Main Business Overview
13.3.5 Lupin Latest Developments
13.4 Zydus Group
13.4.1 Zydus Group Company Information
13.4.2 Zydus Group Endothelin Antagonists Therapeutics Product Portfolios and Specifications
13.4.3 Zydus Group Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Zydus Group Main Business Overview
13.4.5 Zydus Group Latest Developments
13.5 Endo International plc
13.5.1 Endo International plc Company Information
13.5.2 Endo International plc Endothelin Antagonists Therapeutics Product Portfolios and Specifications
13.5.3 Endo International plc Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Endo International plc Main Business Overview
13.5.5 Endo International plc Latest Developments
13.6 Mylan NV
13.6.1 Mylan NV Company Information
13.6.2 Mylan NV Endothelin Antagonists Therapeutics Product Portfolios and Specifications
13.6.3 Mylan NV Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Mylan NV Main Business Overview
13.6.5 Mylan NV Latest Developments
13.7 Teva Pharmaceutical Industries Ltd
13.7.1 Teva Pharmaceutical Industries Ltd Company Information
13.7.2 Teva Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Product Portfolios and Specifications
13.7.3 Teva Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Teva Pharmaceutical Industries Ltd Main Business Overview
13.7.5 Teva Pharmaceutical Industries Ltd Latest Developments
13.8 Sigmapharm Laboratories , LLC
13.8.1 Sigmapharm Laboratories , LLC Company Information
13.8.2 Sigmapharm Laboratories , LLC Endothelin Antagonists Therapeutics Product Portfolios and Specifications
13.8.3 Sigmapharm Laboratories , LLC Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Sigmapharm Laboratories , LLC Main Business Overview
13.8.5 Sigmapharm Laboratories , LLC Latest Developments
13.9 Alembic Pharmaceuticals Limited
13.9.1 Alembic Pharmaceuticals Limited Company Information
13.9.2 Alembic Pharmaceuticals Limited Endothelin Antagonists Therapeutics Product Portfolios and Specifications
13.9.3 Alembic Pharmaceuticals Limited Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Alembic Pharmaceuticals Limited Main Business Overview
13.9.5 Alembic Pharmaceuticals Limited Latest Developments
13.10 Hikma Pharmaceuticals PLC
13.10.1 Hikma Pharmaceuticals PLC Company Information
13.10.2 Hikma Pharmaceuticals PLC Endothelin Antagonists Therapeutics Product Portfolios and Specifications
13.10.3 Hikma Pharmaceuticals PLC Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Hikma Pharmaceuticals PLC Main Business Overview
13.10.5 Hikma Pharmaceuticals PLC Latest Developments
13.11 Amneal Pharmaceuticals LLC
13.11.1 Amneal Pharmaceuticals LLC Company Information
13.11.2 Amneal Pharmaceuticals LLC Endothelin Antagonists Therapeutics Product Portfolios and Specifications
13.11.3 Amneal Pharmaceuticals LLC Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Amneal Pharmaceuticals LLC Main Business Overview
13.11.5 Amneal Pharmaceuticals LLC Latest Developments
13.12 AstraZeneca
13.12.1 AstraZeneca Company Information
13.12.2 AstraZeneca Endothelin Antagonists Therapeutics Product Portfolios and Specifications
13.12.3 AstraZeneca Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 AstraZeneca Main Business Overview
13.12.5 AstraZeneca Latest Developments
13.13 Johnsons & Johnsons Private limited
13.13.1 Johnsons & Johnsons Private limited Company Information
13.13.2 Johnsons & Johnsons Private limited Endothelin Antagonists Therapeutics Product Portfolios and Specifications
13.13.3 Johnsons & Johnsons Private limited Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Johnsons & Johnsons Private limited Main Business Overview
13.13.5 Johnsons & Johnsons Private limited Latest Developments
13.14 GSK Plc
13.14.1 GSK Plc Company Information
13.14.2 GSK Plc Endothelin Antagonists Therapeutics Product Portfolios and Specifications
13.14.3 GSK Plc Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 GSK Plc Main Business Overview
13.14.5 GSK Plc Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Endothelin Antagonists Therapeutics Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Endothelin Antagonists Therapeutics by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Endothelin Antagonists Therapeutics by Country/Region, 2021, 2025 & 2032
2.2 Endothelin Antagonists Therapeutics Segment by Type
2.2.1 Oral
2.2.2 Parenteral
2.2.3 Endothelin Antagonists Therapeutics Sales by Type
2.2.3.1 Global Endothelin Antagonists Therapeutics Sales Market Share by Type (2021-2026)
2.2.3.2 Global Endothelin Antagonists Therapeutics Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Endothelin Antagonists Therapeutics Sale Price by Type (2021-2026)
2.3 Endothelin Antagonists Therapeutics Segment by Application
2.3.1 Cardiovascular Diseases
2.3.2 Scleroderma
2.3.3 Other
2.3.4 Endothelin Antagonists Therapeutics Sales by Application
2.3.4.1 Global Endothelin Antagonists Therapeutics Sale Market Share by Application (2021-2026)
2.3.4.2 Global Endothelin Antagonists Therapeutics Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Endothelin Antagonists Therapeutics Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Endothelin Antagonists Therapeutics Breakdown Data by Company
3.1.1 Global Endothelin Antagonists Therapeutics Annual Sales by Company (2021-2026)
3.1.2 Global Endothelin Antagonists Therapeutics Sales Market Share by Company (2021-2026)
3.2 Global Endothelin Antagonists Therapeutics Annual Revenue by Company (2021-2026)
3.2.1 Global Endothelin Antagonists Therapeutics Revenue by Company (2021-2026)
3.2.2 Global Endothelin Antagonists Therapeutics Revenue Market Share by Company (2021-2026)
3.3 Global Endothelin Antagonists Therapeutics Sale Price by Company
3.4 Key Manufacturers Endothelin Antagonists Therapeutics Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Endothelin Antagonists Therapeutics Product Location Distribution
3.4.2 Players Endothelin Antagonists Therapeutics Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR ENDOTHELIN ANTAGONISTS THERAPEUTICS BY GEOGRAPHIC REGION
4.1 World Historic Endothelin Antagonists Therapeutics Market Size by Geographic Region (2021-2026)
4.1.1 Global Endothelin Antagonists Therapeutics Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Endothelin Antagonists Therapeutics Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Endothelin Antagonists Therapeutics Market Size by Country/Region (2021-2026)
4.2.1 Global Endothelin Antagonists Therapeutics Annual Sales by Country/Region (2021-2026)
4.2.2 Global Endothelin Antagonists Therapeutics Annual Revenue by Country/Region (2021-2026)
4.3 Americas Endothelin Antagonists Therapeutics Sales Growth
4.4 APAC Endothelin Antagonists Therapeutics Sales Growth
4.5 Europe Endothelin Antagonists Therapeutics Sales Growth
4.6 Middle East & Africa Endothelin Antagonists Therapeutics Sales Growth
5 AMERICAS
5.1 Americas Endothelin Antagonists Therapeutics Sales by Country
5.1.1 Americas Endothelin Antagonists Therapeutics Sales by Country (2021-2026)
5.1.2 Americas Endothelin Antagonists Therapeutics Revenue by Country (2021-2026)
5.2 Americas Endothelin Antagonists Therapeutics Sales by Type (2021-2026)
5.3 Americas Endothelin Antagonists Therapeutics Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Endothelin Antagonists Therapeutics Sales by Region
6.1.1 APAC Endothelin Antagonists Therapeutics Sales by Region (2021-2026)
6.1.2 APAC Endothelin Antagonists Therapeutics Revenue by Region (2021-2026)
6.2 APAC Endothelin Antagonists Therapeutics Sales by Type (2021-2026)
6.3 APAC Endothelin Antagonists Therapeutics Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Endothelin Antagonists Therapeutics by Country
7.1.1 Europe Endothelin Antagonists Therapeutics Sales by Country (2021-2026)
7.1.2 Europe Endothelin Antagonists Therapeutics Revenue by Country (2021-2026)
7.2 Europe Endothelin Antagonists Therapeutics Sales by Type (2021-2026)
7.3 Europe Endothelin Antagonists Therapeutics Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Endothelin Antagonists Therapeutics by Country
8.1.1 Middle East & Africa Endothelin Antagonists Therapeutics Sales by Country (2021-2026)
8.1.2 Middle East & Africa Endothelin Antagonists Therapeutics Revenue by Country (2021-2026)
8.2 Middle East & Africa Endothelin Antagonists Therapeutics Sales by Type (2021-2026)
8.3 Middle East & Africa Endothelin Antagonists Therapeutics Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Endothelin Antagonists Therapeutics
10.3 Manufacturing Process Analysis of Endothelin Antagonists Therapeutics
10.4 Industry Chain Structure of Endothelin Antagonists Therapeutics
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Endothelin Antagonists Therapeutics Distributors
11.3 Endothelin Antagonists Therapeutics Customer
12 WORLD FORECAST REVIEW FOR ENDOTHELIN ANTAGONISTS THERAPEUTICS BY GEOGRAPHIC REGION
12.1 Global Endothelin Antagonists Therapeutics Market Size Forecast by Region
12.1.1 Global Endothelin Antagonists Therapeutics Forecast by Region (2027-2032)
12.1.2 Global Endothelin Antagonists Therapeutics Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Endothelin Antagonists Therapeutics Forecast by Type (2027-2032)
12.7 Global Endothelin Antagonists Therapeutics Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Gilead Sciences, Inc
13.1.1 Gilead Sciences, Inc Company Information
13.1.2 Gilead Sciences, Inc Endothelin Antagonists Therapeutics Product Portfolios and Specifications
13.1.3 Gilead Sciences, Inc Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Gilead Sciences, Inc Main Business Overview
13.1.5 Gilead Sciences, Inc Latest Developments
13.2 Sun Pharmaceutical Industries Ltd
13.2.1 Sun Pharmaceutical Industries Ltd Company Information
13.2.2 Sun Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Product Portfolios and Specifications
13.2.3 Sun Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Sun Pharmaceutical Industries Ltd Main Business Overview
13.2.5 Sun Pharmaceutical Industries Ltd Latest Developments
13.3 Lupin
13.3.1 Lupin Company Information
13.3.2 Lupin Endothelin Antagonists Therapeutics Product Portfolios and Specifications
13.3.3 Lupin Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Lupin Main Business Overview
13.3.5 Lupin Latest Developments
13.4 Zydus Group
13.4.1 Zydus Group Company Information
13.4.2 Zydus Group Endothelin Antagonists Therapeutics Product Portfolios and Specifications
13.4.3 Zydus Group Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Zydus Group Main Business Overview
13.4.5 Zydus Group Latest Developments
13.5 Endo International plc
13.5.1 Endo International plc Company Information
13.5.2 Endo International plc Endothelin Antagonists Therapeutics Product Portfolios and Specifications
13.5.3 Endo International plc Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Endo International plc Main Business Overview
13.5.5 Endo International plc Latest Developments
13.6 Mylan NV
13.6.1 Mylan NV Company Information
13.6.2 Mylan NV Endothelin Antagonists Therapeutics Product Portfolios and Specifications
13.6.3 Mylan NV Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Mylan NV Main Business Overview
13.6.5 Mylan NV Latest Developments
13.7 Teva Pharmaceutical Industries Ltd
13.7.1 Teva Pharmaceutical Industries Ltd Company Information
13.7.2 Teva Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Product Portfolios and Specifications
13.7.3 Teva Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Teva Pharmaceutical Industries Ltd Main Business Overview
13.7.5 Teva Pharmaceutical Industries Ltd Latest Developments
13.8 Sigmapharm Laboratories , LLC
13.8.1 Sigmapharm Laboratories , LLC Company Information
13.8.2 Sigmapharm Laboratories , LLC Endothelin Antagonists Therapeutics Product Portfolios and Specifications
13.8.3 Sigmapharm Laboratories , LLC Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Sigmapharm Laboratories , LLC Main Business Overview
13.8.5 Sigmapharm Laboratories , LLC Latest Developments
13.9 Alembic Pharmaceuticals Limited
13.9.1 Alembic Pharmaceuticals Limited Company Information
13.9.2 Alembic Pharmaceuticals Limited Endothelin Antagonists Therapeutics Product Portfolios and Specifications
13.9.3 Alembic Pharmaceuticals Limited Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Alembic Pharmaceuticals Limited Main Business Overview
13.9.5 Alembic Pharmaceuticals Limited Latest Developments
13.10 Hikma Pharmaceuticals PLC
13.10.1 Hikma Pharmaceuticals PLC Company Information
13.10.2 Hikma Pharmaceuticals PLC Endothelin Antagonists Therapeutics Product Portfolios and Specifications
13.10.3 Hikma Pharmaceuticals PLC Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Hikma Pharmaceuticals PLC Main Business Overview
13.10.5 Hikma Pharmaceuticals PLC Latest Developments
13.11 Amneal Pharmaceuticals LLC
13.11.1 Amneal Pharmaceuticals LLC Company Information
13.11.2 Amneal Pharmaceuticals LLC Endothelin Antagonists Therapeutics Product Portfolios and Specifications
13.11.3 Amneal Pharmaceuticals LLC Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Amneal Pharmaceuticals LLC Main Business Overview
13.11.5 Amneal Pharmaceuticals LLC Latest Developments
13.12 AstraZeneca
13.12.1 AstraZeneca Company Information
13.12.2 AstraZeneca Endothelin Antagonists Therapeutics Product Portfolios and Specifications
13.12.3 AstraZeneca Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 AstraZeneca Main Business Overview
13.12.5 AstraZeneca Latest Developments
13.13 Johnsons & Johnsons Private limited
13.13.1 Johnsons & Johnsons Private limited Company Information
13.13.2 Johnsons & Johnsons Private limited Endothelin Antagonists Therapeutics Product Portfolios and Specifications
13.13.3 Johnsons & Johnsons Private limited Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Johnsons & Johnsons Private limited Main Business Overview
13.13.5 Johnsons & Johnsons Private limited Latest Developments
13.14 GSK Plc
13.14.1 GSK Plc Company Information
13.14.2 GSK Plc Endothelin Antagonists Therapeutics Product Portfolios and Specifications
13.14.3 GSK Plc Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 GSK Plc Main Business Overview
13.14.5 GSK Plc Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Endothelin Antagonists Therapeutics Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Endothelin Antagonists Therapeutics Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Oral
Table 4. Major Players of Parenteral
Table 5. Global Endothelin Antagonists Therapeutics Sales by Type (2021-2026) & (K Units)
Table 6. Global Endothelin Antagonists Therapeutics Sales Market Share by Type (2021-2026)
Table 7. Global Endothelin Antagonists Therapeutics Revenue by Type (2021-2026) & ($ million)
Table 8. Global Endothelin Antagonists Therapeutics Revenue Market Share by Type (2021-2026)
Table 9. Global Endothelin Antagonists Therapeutics Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Global Endothelin Antagonists Therapeutics Sale by Application (2021-2026) & (K Units)
Table 11. Global Endothelin Antagonists Therapeutics Sale Market Share by Application (2021-2026)
Table 12. Global Endothelin Antagonists Therapeutics Revenue by Application (2021-2026) & ($ million)
Table 13. Global Endothelin Antagonists Therapeutics Revenue Market Share by Application (2021-2026)
Table 14. Global Endothelin Antagonists Therapeutics Sale Price by Application (2021-2026) & (US$/Unit)
Table 15. Global Endothelin Antagonists Therapeutics Sales by Company (2021-2026) & (K Units)
Table 16. Global Endothelin Antagonists Therapeutics Sales Market Share by Company (2021-2026)
Table 17. Global Endothelin Antagonists Therapeutics Revenue by Company (2021-2026) & ($ millions)
Table 18. Global Endothelin Antagonists Therapeutics Revenue Market Share by Company (2021-2026)
Table 19. Global Endothelin Antagonists Therapeutics Sale Price by Company (2021-2026) & (US$/Unit)
Table 20. Key Manufacturers Endothelin Antagonists Therapeutics Producing Area Distribution and Sales Area
Table 21. Players Endothelin Antagonists Therapeutics Products Offered
Table 22. Endothelin Antagonists Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Endothelin Antagonists Therapeutics Sales by Geographic Region (2021-2026) & (K Units)
Table 26. Global Endothelin Antagonists Therapeutics Sales Market Share Geographic Region (2021-2026)
Table 27. Global Endothelin Antagonists Therapeutics Revenue by Geographic Region (2021-2026) & ($ millions)
Table 28. Global Endothelin Antagonists Therapeutics Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global Endothelin Antagonists Therapeutics Sales by Country/Region (2021-2026) & (K Units)
Table 30. Global Endothelin Antagonists Therapeutics Sales Market Share by Country/Region (2021-2026)
Table 31. Global Endothelin Antagonists Therapeutics Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Endothelin Antagonists Therapeutics Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Endothelin Antagonists Therapeutics Sales by Country (2021-2026) & (K Units)
Table 34. Americas Endothelin Antagonists Therapeutics Sales Market Share by Country (2021-2026)
Table 35. Americas Endothelin Antagonists Therapeutics Revenue by Country (2021-2026) & ($ millions)
Table 36. Americas Endothelin Antagonists Therapeutics Sales by Type (2021-2026) & (K Units)
Table 37. Americas Endothelin Antagonists Therapeutics Sales by Application (2021-2026) & (K Units)
Table 38. APAC Endothelin Antagonists Therapeutics Sales by Region (2021-2026) & (K Units)
Table 39. APAC Endothelin Antagonists Therapeutics Sales Market Share by Region (2021-2026)
Table 40. APAC Endothelin Antagonists Therapeutics Revenue by Region (2021-2026) & ($ millions)
Table 41. APAC Endothelin Antagonists Therapeutics Sales by Type (2021-2026) & (K Units)
Table 42. APAC Endothelin Antagonists Therapeutics Sales by Application (2021-2026) & (K Units)
Table 43. Europe Endothelin Antagonists Therapeutics Sales by Country (2021-2026) & (K Units)
Table 44. Europe Endothelin Antagonists Therapeutics Revenue by Country (2021-2026) & ($ millions)
Table 45. Europe Endothelin Antagonists Therapeutics Sales by Type (2021-2026) & (K Units)
Table 46. Europe Endothelin Antagonists Therapeutics Sales by Application (2021-2026) & (K Units)
Table 47. Middle East & Africa Endothelin Antagonists Therapeutics Sales by Country (2021-2026) & (K Units)
Table 48. Middle East & Africa Endothelin Antagonists Therapeutics Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa Endothelin Antagonists Therapeutics Sales by Type (2021-2026) & (K Units)
Table 50. Middle East & Africa Endothelin Antagonists Therapeutics Sales by Application (2021-2026) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Endothelin Antagonists Therapeutics
Table 52. Key Market Challenges & Risks of Endothelin Antagonists Therapeutics
Table 53. Key Industry Trends of Endothelin Antagonists Therapeutics
Table 54. Endothelin Antagonists Therapeutics Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Endothelin Antagonists Therapeutics Distributors List
Table 57. Endothelin Antagonists Therapeutics Customer List
Table 58. Global Endothelin Antagonists Therapeutics Sales Forecast by Region (2027-2032) & (K Units)
Table 59. Global Endothelin Antagonists Therapeutics Revenue Forecast by Region (2027-2032) & ($ millions)
Table 60. Americas Endothelin Antagonists Therapeutics Sales Forecast by Country (2027-2032) & (K Units)
Table 61. Americas Endothelin Antagonists Therapeutics Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 62. APAC Endothelin Antagonists Therapeutics Sales Forecast by Region (2027-2032) & (K Units)
Table 63. APAC Endothelin Antagonists Therapeutics Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Europe Endothelin Antagonists Therapeutics Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Europe Endothelin Antagonists Therapeutics Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. Middle East & Africa Endothelin Antagonists Therapeutics Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Middle East & Africa Endothelin Antagonists Therapeutics Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Global Endothelin Antagonists Therapeutics Sales Forecast by Type (2027-2032) & (K Units)
Table 69. Global Endothelin Antagonists Therapeutics Revenue Forecast by Type (2027-2032) & ($ millions)
Table 70. Global Endothelin Antagonists Therapeutics Sales Forecast by Application (2027-2032) & (K Units)
Table 71. Global Endothelin Antagonists Therapeutics Revenue Forecast by Application (2027-2032) & ($ millions)
Table 72. Gilead Sciences, Inc Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 73. Gilead Sciences, Inc Endothelin Antagonists Therapeutics Product Portfolios and Specifications
Table 74. Gilead Sciences, Inc Endothelin Antagonists Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. Gilead Sciences, Inc Main Business
Table 76. Gilead Sciences, Inc Latest Developments
Table 77. Sun Pharmaceutical Industries Ltd Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 78. Sun Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Product Portfolios and Specifications
Table 79. Sun Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Sun Pharmaceutical Industries Ltd Main Business
Table 81. Sun Pharmaceutical Industries Ltd Latest Developments
Table 82. Lupin Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 83. Lupin Endothelin Antagonists Therapeutics Product Portfolios and Specifications
Table 84. Lupin Endothelin Antagonists Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Lupin Main Business
Table 86. Lupin Latest Developments
Table 87. Zydus Group Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 88. Zydus Group Endothelin Antagonists Therapeutics Product Portfolios and Specifications
Table 89. Zydus Group Endothelin Antagonists Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Zydus Group Main Business
Table 91. Zydus Group Latest Developments
Table 92. Endo International plc Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 93. Endo International plc Endothelin Antagonists Therapeutics Product Portfolios and Specifications
Table 94. Endo International plc Endothelin Antagonists Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. Endo International plc Main Business
Table 96. Endo International plc Latest Developments
Table 97. Mylan NV Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 98. Mylan NV Endothelin Antagonists Therapeutics Product Portfolios and Specifications
Table 99. Mylan NV Endothelin Antagonists Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. Mylan NV Main Business
Table 101. Mylan NV Latest Developments
Table 102. Teva Pharmaceutical Industries Ltd Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 103. Teva Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Product Portfolios and Specifications
Table 104. Teva Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 105. Teva Pharmaceutical Industries Ltd Main Business
Table 106. Teva Pharmaceutical Industries Ltd Latest Developments
Table 107. Sigmapharm Laboratories , LLC Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 108. Sigmapharm Laboratories , LLC Endothelin Antagonists Therapeutics Product Portfolios and Specifications
Table 109. Sigmapharm Laboratories , LLC Endothelin Antagonists Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 110. Sigmapharm Laboratories , LLC Main Business
Table 111. Sigmapharm Laboratories , LLC Latest Developments
Table 112. Alembic Pharmaceuticals Limited Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 113. Alembic Pharmaceuticals Limited Endothelin Antagonists Therapeutics Product Portfolios and Specifications
Table 114. Alembic Pharmaceuticals Limited Endothelin Antagonists Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 115. Alembic Pharmaceuticals Limited Main Business
Table 116. Alembic Pharmaceuticals Limited Latest Developments
Table 117. Hikma Pharmaceuticals PLC Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 118. Hikma Pharmaceuticals PLC Endothelin Antagonists Therapeutics Product Portfolios and Specifications
Table 119. Hikma Pharmaceuticals PLC Endothelin Antagonists Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 120. Hikma Pharmaceuticals PLC Main Business
Table 121. Hikma Pharmaceuticals PLC Latest Developments
Table 122. Amneal Pharmaceuticals LLC Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 123. Amneal Pharmaceuticals LLC Endothelin Antagonists Therapeutics Product Portfolios and Specifications
Table 124. Amneal Pharmaceuticals LLC Endothelin Antagonists Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 125. Amneal Pharmaceuticals LLC Main Business
Table 126. Amneal Pharmaceuticals LLC Latest Developments
Table 127. AstraZeneca Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 128. AstraZeneca Endothelin Antagonists Therapeutics Product Portfolios and Specifications
Table 129. AstraZeneca Endothelin Antagonists Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 130. AstraZeneca Main Business
Table 131. AstraZeneca Latest Developments
Table 132. Johnsons & Johnsons Private limited Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 133. Johnsons & Johnsons Private limited Endothelin Antagonists Therapeutics Product Portfolios and Specifications
Table 134. Johnsons & Johnsons Private limited Endothelin Antagonists Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 135. Johnsons & Johnsons Private limited Main Business
Table 136. Johnsons & Johnsons Private limited Latest Developments
Table 137. GSK Plc Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 138. GSK Plc Endothelin Antagonists Therapeutics Product Portfolios and Specifications
Table 139. GSK Plc Endothelin Antagonists Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 140. GSK Plc Main Business
Table 141. GSK Plc Latest Developments
Table 1. Endothelin Antagonists Therapeutics Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Endothelin Antagonists Therapeutics Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Oral
Table 4. Major Players of Parenteral
Table 5. Global Endothelin Antagonists Therapeutics Sales by Type (2021-2026) & (K Units)
Table 6. Global Endothelin Antagonists Therapeutics Sales Market Share by Type (2021-2026)
Table 7. Global Endothelin Antagonists Therapeutics Revenue by Type (2021-2026) & ($ million)
Table 8. Global Endothelin Antagonists Therapeutics Revenue Market Share by Type (2021-2026)
Table 9. Global Endothelin Antagonists Therapeutics Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Global Endothelin Antagonists Therapeutics Sale by Application (2021-2026) & (K Units)
Table 11. Global Endothelin Antagonists Therapeutics Sale Market Share by Application (2021-2026)
Table 12. Global Endothelin Antagonists Therapeutics Revenue by Application (2021-2026) & ($ million)
Table 13. Global Endothelin Antagonists Therapeutics Revenue Market Share by Application (2021-2026)
Table 14. Global Endothelin Antagonists Therapeutics Sale Price by Application (2021-2026) & (US$/Unit)
Table 15. Global Endothelin Antagonists Therapeutics Sales by Company (2021-2026) & (K Units)
Table 16. Global Endothelin Antagonists Therapeutics Sales Market Share by Company (2021-2026)
Table 17. Global Endothelin Antagonists Therapeutics Revenue by Company (2021-2026) & ($ millions)
Table 18. Global Endothelin Antagonists Therapeutics Revenue Market Share by Company (2021-2026)
Table 19. Global Endothelin Antagonists Therapeutics Sale Price by Company (2021-2026) & (US$/Unit)
Table 20. Key Manufacturers Endothelin Antagonists Therapeutics Producing Area Distribution and Sales Area
Table 21. Players Endothelin Antagonists Therapeutics Products Offered
Table 22. Endothelin Antagonists Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Endothelin Antagonists Therapeutics Sales by Geographic Region (2021-2026) & (K Units)
Table 26. Global Endothelin Antagonists Therapeutics Sales Market Share Geographic Region (2021-2026)
Table 27. Global Endothelin Antagonists Therapeutics Revenue by Geographic Region (2021-2026) & ($ millions)
Table 28. Global Endothelin Antagonists Therapeutics Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global Endothelin Antagonists Therapeutics Sales by Country/Region (2021-2026) & (K Units)
Table 30. Global Endothelin Antagonists Therapeutics Sales Market Share by Country/Region (2021-2026)
Table 31. Global Endothelin Antagonists Therapeutics Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Endothelin Antagonists Therapeutics Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Endothelin Antagonists Therapeutics Sales by Country (2021-2026) & (K Units)
Table 34. Americas Endothelin Antagonists Therapeutics Sales Market Share by Country (2021-2026)
Table 35. Americas Endothelin Antagonists Therapeutics Revenue by Country (2021-2026) & ($ millions)
Table 36. Americas Endothelin Antagonists Therapeutics Sales by Type (2021-2026) & (K Units)
Table 37. Americas Endothelin Antagonists Therapeutics Sales by Application (2021-2026) & (K Units)
Table 38. APAC Endothelin Antagonists Therapeutics Sales by Region (2021-2026) & (K Units)
Table 39. APAC Endothelin Antagonists Therapeutics Sales Market Share by Region (2021-2026)
Table 40. APAC Endothelin Antagonists Therapeutics Revenue by Region (2021-2026) & ($ millions)
Table 41. APAC Endothelin Antagonists Therapeutics Sales by Type (2021-2026) & (K Units)
Table 42. APAC Endothelin Antagonists Therapeutics Sales by Application (2021-2026) & (K Units)
Table 43. Europe Endothelin Antagonists Therapeutics Sales by Country (2021-2026) & (K Units)
Table 44. Europe Endothelin Antagonists Therapeutics Revenue by Country (2021-2026) & ($ millions)
Table 45. Europe Endothelin Antagonists Therapeutics Sales by Type (2021-2026) & (K Units)
Table 46. Europe Endothelin Antagonists Therapeutics Sales by Application (2021-2026) & (K Units)
Table 47. Middle East & Africa Endothelin Antagonists Therapeutics Sales by Country (2021-2026) & (K Units)
Table 48. Middle East & Africa Endothelin Antagonists Therapeutics Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa Endothelin Antagonists Therapeutics Sales by Type (2021-2026) & (K Units)
Table 50. Middle East & Africa Endothelin Antagonists Therapeutics Sales by Application (2021-2026) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Endothelin Antagonists Therapeutics
Table 52. Key Market Challenges & Risks of Endothelin Antagonists Therapeutics
Table 53. Key Industry Trends of Endothelin Antagonists Therapeutics
Table 54. Endothelin Antagonists Therapeutics Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Endothelin Antagonists Therapeutics Distributors List
Table 57. Endothelin Antagonists Therapeutics Customer List
Table 58. Global Endothelin Antagonists Therapeutics Sales Forecast by Region (2027-2032) & (K Units)
Table 59. Global Endothelin Antagonists Therapeutics Revenue Forecast by Region (2027-2032) & ($ millions)
Table 60. Americas Endothelin Antagonists Therapeutics Sales Forecast by Country (2027-2032) & (K Units)
Table 61. Americas Endothelin Antagonists Therapeutics Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 62. APAC Endothelin Antagonists Therapeutics Sales Forecast by Region (2027-2032) & (K Units)
Table 63. APAC Endothelin Antagonists Therapeutics Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Europe Endothelin Antagonists Therapeutics Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Europe Endothelin Antagonists Therapeutics Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. Middle East & Africa Endothelin Antagonists Therapeutics Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Middle East & Africa Endothelin Antagonists Therapeutics Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Global Endothelin Antagonists Therapeutics Sales Forecast by Type (2027-2032) & (K Units)
Table 69. Global Endothelin Antagonists Therapeutics Revenue Forecast by Type (2027-2032) & ($ millions)
Table 70. Global Endothelin Antagonists Therapeutics Sales Forecast by Application (2027-2032) & (K Units)
Table 71. Global Endothelin Antagonists Therapeutics Revenue Forecast by Application (2027-2032) & ($ millions)
Table 72. Gilead Sciences, Inc Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 73. Gilead Sciences, Inc Endothelin Antagonists Therapeutics Product Portfolios and Specifications
Table 74. Gilead Sciences, Inc Endothelin Antagonists Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. Gilead Sciences, Inc Main Business
Table 76. Gilead Sciences, Inc Latest Developments
Table 77. Sun Pharmaceutical Industries Ltd Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 78. Sun Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Product Portfolios and Specifications
Table 79. Sun Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Sun Pharmaceutical Industries Ltd Main Business
Table 81. Sun Pharmaceutical Industries Ltd Latest Developments
Table 82. Lupin Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 83. Lupin Endothelin Antagonists Therapeutics Product Portfolios and Specifications
Table 84. Lupin Endothelin Antagonists Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Lupin Main Business
Table 86. Lupin Latest Developments
Table 87. Zydus Group Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 88. Zydus Group Endothelin Antagonists Therapeutics Product Portfolios and Specifications
Table 89. Zydus Group Endothelin Antagonists Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Zydus Group Main Business
Table 91. Zydus Group Latest Developments
Table 92. Endo International plc Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 93. Endo International plc Endothelin Antagonists Therapeutics Product Portfolios and Specifications
Table 94. Endo International plc Endothelin Antagonists Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. Endo International plc Main Business
Table 96. Endo International plc Latest Developments
Table 97. Mylan NV Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 98. Mylan NV Endothelin Antagonists Therapeutics Product Portfolios and Specifications
Table 99. Mylan NV Endothelin Antagonists Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. Mylan NV Main Business
Table 101. Mylan NV Latest Developments
Table 102. Teva Pharmaceutical Industries Ltd Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 103. Teva Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Product Portfolios and Specifications
Table 104. Teva Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 105. Teva Pharmaceutical Industries Ltd Main Business
Table 106. Teva Pharmaceutical Industries Ltd Latest Developments
Table 107. Sigmapharm Laboratories , LLC Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 108. Sigmapharm Laboratories , LLC Endothelin Antagonists Therapeutics Product Portfolios and Specifications
Table 109. Sigmapharm Laboratories , LLC Endothelin Antagonists Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 110. Sigmapharm Laboratories , LLC Main Business
Table 111. Sigmapharm Laboratories , LLC Latest Developments
Table 112. Alembic Pharmaceuticals Limited Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 113. Alembic Pharmaceuticals Limited Endothelin Antagonists Therapeutics Product Portfolios and Specifications
Table 114. Alembic Pharmaceuticals Limited Endothelin Antagonists Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 115. Alembic Pharmaceuticals Limited Main Business
Table 116. Alembic Pharmaceuticals Limited Latest Developments
Table 117. Hikma Pharmaceuticals PLC Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 118. Hikma Pharmaceuticals PLC Endothelin Antagonists Therapeutics Product Portfolios and Specifications
Table 119. Hikma Pharmaceuticals PLC Endothelin Antagonists Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 120. Hikma Pharmaceuticals PLC Main Business
Table 121. Hikma Pharmaceuticals PLC Latest Developments
Table 122. Amneal Pharmaceuticals LLC Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 123. Amneal Pharmaceuticals LLC Endothelin Antagonists Therapeutics Product Portfolios and Specifications
Table 124. Amneal Pharmaceuticals LLC Endothelin Antagonists Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 125. Amneal Pharmaceuticals LLC Main Business
Table 126. Amneal Pharmaceuticals LLC Latest Developments
Table 127. AstraZeneca Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 128. AstraZeneca Endothelin Antagonists Therapeutics Product Portfolios and Specifications
Table 129. AstraZeneca Endothelin Antagonists Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 130. AstraZeneca Main Business
Table 131. AstraZeneca Latest Developments
Table 132. Johnsons & Johnsons Private limited Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 133. Johnsons & Johnsons Private limited Endothelin Antagonists Therapeutics Product Portfolios and Specifications
Table 134. Johnsons & Johnsons Private limited Endothelin Antagonists Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 135. Johnsons & Johnsons Private limited Main Business
Table 136. Johnsons & Johnsons Private limited Latest Developments
Table 137. GSK Plc Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 138. GSK Plc Endothelin Antagonists Therapeutics Product Portfolios and Specifications
Table 139. GSK Plc Endothelin Antagonists Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 140. GSK Plc Main Business
Table 141. GSK Plc Latest Developments
LIST OF FIGURES
Figure 1. Picture of Endothelin Antagonists Therapeutics
Figure 2. Endothelin Antagonists Therapeutics Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Endothelin Antagonists Therapeutics Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Endothelin Antagonists Therapeutics Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Endothelin Antagonists Therapeutics Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Endothelin Antagonists Therapeutics Sales Market Share by Country/Region (2025)
Figure 10. Endothelin Antagonists Therapeutics Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Oral
Figure 12. Product Picture of Parenteral
Figure 13. Global Endothelin Antagonists Therapeutics Sales Market Share by Type in 2026
Figure 14. Global Endothelin Antagonists Therapeutics Revenue Market Share by Type (2021-2026)
Figure 15. Endothelin Antagonists Therapeutics Consumed in Cardiovascular Diseases
Figure 16. Global Endothelin Antagonists Therapeutics Market: Cardiovascular Diseases (2021-2026) & (K Units)
Figure 17. Endothelin Antagonists Therapeutics Consumed in Scleroderma
Figure 18. Global Endothelin Antagonists Therapeutics Market: Scleroderma (2021-2026) & (K Units)
Figure 19. Endothelin Antagonists Therapeutics Consumed in Other
Figure 20. Global Endothelin Antagonists Therapeutics Market: Other (2021-2026) & (K Units)
Figure 21. Global Endothelin Antagonists Therapeutics Sale Market Share by Application (2025)
Figure 22. Global Endothelin Antagonists Therapeutics Revenue Market Share by Application in 2026
Figure 23. Endothelin Antagonists Therapeutics Sales by Company in 2026 (K Units)
Figure 24. Global Endothelin Antagonists Therapeutics Sales Market Share by Company in 2026
Figure 25. Endothelin Antagonists Therapeutics Revenue by Company in 2026 ($ millions)
Figure 26. Global Endothelin Antagonists Therapeutics Revenue Market Share by Company in 2026
Figure 27. Global Endothelin Antagonists Therapeutics Sales Market Share by Geographic Region (2021-2026)
Figure 28. Global Endothelin Antagonists Therapeutics Revenue Market Share by Geographic Region in 2026
Figure 29. Americas Endothelin Antagonists Therapeutics Sales 2021-2026 (K Units)
Figure 30. Americas Endothelin Antagonists Therapeutics Revenue 2021-2026 ($ millions)
Figure 31. APAC Endothelin Antagonists Therapeutics Sales 2021-2026 (K Units)
Figure 32. APAC Endothelin Antagonists Therapeutics Revenue 2021-2026 ($ millions)
Figure 33. Europe Endothelin Antagonists Therapeutics Sales 2021-2026 (K Units)
Figure 34. Europe Endothelin Antagonists Therapeutics Revenue 2021-2026 ($ millions)
Figure 35. Middle East & Africa Endothelin Antagonists Therapeutics Sales 2021-2026 (K Units)
Figure 36. Middle East & Africa Endothelin Antagonists Therapeutics Revenue 2021-2026 ($ millions)
Figure 37. Americas Endothelin Antagonists Therapeutics Sales Market Share by Country in 2026
Figure 38. Americas Endothelin Antagonists Therapeutics Revenue Market Share by Country (2021-2026)
Figure 39. Americas Endothelin Antagonists Therapeutics Sales Market Share by Type (2021-2026)
Figure 40. Americas Endothelin Antagonists Therapeutics Sales Market Share by Application (2021-2026)
Figure 41. United States Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 42. Canada Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 43. Mexico Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 44. Brazil Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 45. APAC Endothelin Antagonists Therapeutics Sales Market Share by Region in 2026
Figure 46. APAC Endothelin Antagonists Therapeutics Revenue Market Share by Region (2021-2026)
Figure 47. APAC Endothelin Antagonists Therapeutics Sales Market Share by Type (2021-2026)
Figure 48. APAC Endothelin Antagonists Therapeutics Sales Market Share by Application (2021-2026)
Figure 49. China Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 50. Japan Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 51. South Korea Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 52. Southeast Asia Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 53. India Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 54. Australia Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 55. China Taiwan Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 56. Europe Endothelin Antagonists Therapeutics Sales Market Share by Country in 2026
Figure 57. Europe Endothelin Antagonists Therapeutics Revenue Market Share by Country (2021-2026)
Figure 58. Europe Endothelin Antagonists Therapeutics Sales Market Share by Type (2021-2026)
Figure 59. Europe Endothelin Antagonists Therapeutics Sales Market Share by Application (2021-2026)
Figure 60. Germany Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 61. France Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 62. UK Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 63. Italy Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 64. Russia Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 65. Middle East & Africa Endothelin Antagonists Therapeutics Sales Market Share by Country (2021-2026)
Figure 66. Middle East & Africa Endothelin Antagonists Therapeutics Sales Market Share by Type (2021-2026)
Figure 67. Middle East & Africa Endothelin Antagonists Therapeutics Sales Market Share by Application (2021-2026)
Figure 68. Egypt Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 69. South Africa Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 70. Israel Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 71. Turkey Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 72. GCC Countries Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Endothelin Antagonists Therapeutics in 2026
Figure 74. Manufacturing Process Analysis of Endothelin Antagonists Therapeutics
Figure 75. Industry Chain Structure of Endothelin Antagonists Therapeutics
Figure 76. Channels of Distribution
Figure 77. Global Endothelin Antagonists Therapeutics Sales Market Forecast by Region (2027-2032)
Figure 78. Global Endothelin Antagonists Therapeutics Revenue Market Share Forecast by Region (2027-2032)
Figure 79. Global Endothelin Antagonists Therapeutics Sales Market Share Forecast by Type (2027-2032)
Figure 80. Global Endothelin Antagonists Therapeutics Revenue Market Share Forecast by Type (2027-2032)
Figure 81. Global Endothelin Antagonists Therapeutics Sales Market Share Forecast by Application (2027-2032)
Figure 82. Global Endothelin Antagonists Therapeutics Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Endothelin Antagonists Therapeutics
Figure 2. Endothelin Antagonists Therapeutics Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Endothelin Antagonists Therapeutics Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Endothelin Antagonists Therapeutics Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Endothelin Antagonists Therapeutics Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Endothelin Antagonists Therapeutics Sales Market Share by Country/Region (2025)
Figure 10. Endothelin Antagonists Therapeutics Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Oral
Figure 12. Product Picture of Parenteral
Figure 13. Global Endothelin Antagonists Therapeutics Sales Market Share by Type in 2026
Figure 14. Global Endothelin Antagonists Therapeutics Revenue Market Share by Type (2021-2026)
Figure 15. Endothelin Antagonists Therapeutics Consumed in Cardiovascular Diseases
Figure 16. Global Endothelin Antagonists Therapeutics Market: Cardiovascular Diseases (2021-2026) & (K Units)
Figure 17. Endothelin Antagonists Therapeutics Consumed in Scleroderma
Figure 18. Global Endothelin Antagonists Therapeutics Market: Scleroderma (2021-2026) & (K Units)
Figure 19. Endothelin Antagonists Therapeutics Consumed in Other
Figure 20. Global Endothelin Antagonists Therapeutics Market: Other (2021-2026) & (K Units)
Figure 21. Global Endothelin Antagonists Therapeutics Sale Market Share by Application (2025)
Figure 22. Global Endothelin Antagonists Therapeutics Revenue Market Share by Application in 2026
Figure 23. Endothelin Antagonists Therapeutics Sales by Company in 2026 (K Units)
Figure 24. Global Endothelin Antagonists Therapeutics Sales Market Share by Company in 2026
Figure 25. Endothelin Antagonists Therapeutics Revenue by Company in 2026 ($ millions)
Figure 26. Global Endothelin Antagonists Therapeutics Revenue Market Share by Company in 2026
Figure 27. Global Endothelin Antagonists Therapeutics Sales Market Share by Geographic Region (2021-2026)
Figure 28. Global Endothelin Antagonists Therapeutics Revenue Market Share by Geographic Region in 2026
Figure 29. Americas Endothelin Antagonists Therapeutics Sales 2021-2026 (K Units)
Figure 30. Americas Endothelin Antagonists Therapeutics Revenue 2021-2026 ($ millions)
Figure 31. APAC Endothelin Antagonists Therapeutics Sales 2021-2026 (K Units)
Figure 32. APAC Endothelin Antagonists Therapeutics Revenue 2021-2026 ($ millions)
Figure 33. Europe Endothelin Antagonists Therapeutics Sales 2021-2026 (K Units)
Figure 34. Europe Endothelin Antagonists Therapeutics Revenue 2021-2026 ($ millions)
Figure 35. Middle East & Africa Endothelin Antagonists Therapeutics Sales 2021-2026 (K Units)
Figure 36. Middle East & Africa Endothelin Antagonists Therapeutics Revenue 2021-2026 ($ millions)
Figure 37. Americas Endothelin Antagonists Therapeutics Sales Market Share by Country in 2026
Figure 38. Americas Endothelin Antagonists Therapeutics Revenue Market Share by Country (2021-2026)
Figure 39. Americas Endothelin Antagonists Therapeutics Sales Market Share by Type (2021-2026)
Figure 40. Americas Endothelin Antagonists Therapeutics Sales Market Share by Application (2021-2026)
Figure 41. United States Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 42. Canada Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 43. Mexico Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 44. Brazil Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 45. APAC Endothelin Antagonists Therapeutics Sales Market Share by Region in 2026
Figure 46. APAC Endothelin Antagonists Therapeutics Revenue Market Share by Region (2021-2026)
Figure 47. APAC Endothelin Antagonists Therapeutics Sales Market Share by Type (2021-2026)
Figure 48. APAC Endothelin Antagonists Therapeutics Sales Market Share by Application (2021-2026)
Figure 49. China Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 50. Japan Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 51. South Korea Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 52. Southeast Asia Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 53. India Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 54. Australia Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 55. China Taiwan Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 56. Europe Endothelin Antagonists Therapeutics Sales Market Share by Country in 2026
Figure 57. Europe Endothelin Antagonists Therapeutics Revenue Market Share by Country (2021-2026)
Figure 58. Europe Endothelin Antagonists Therapeutics Sales Market Share by Type (2021-2026)
Figure 59. Europe Endothelin Antagonists Therapeutics Sales Market Share by Application (2021-2026)
Figure 60. Germany Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 61. France Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 62. UK Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 63. Italy Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 64. Russia Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 65. Middle East & Africa Endothelin Antagonists Therapeutics Sales Market Share by Country (2021-2026)
Figure 66. Middle East & Africa Endothelin Antagonists Therapeutics Sales Market Share by Type (2021-2026)
Figure 67. Middle East & Africa Endothelin Antagonists Therapeutics Sales Market Share by Application (2021-2026)
Figure 68. Egypt Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 69. South Africa Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 70. Israel Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 71. Turkey Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 72. GCC Countries Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Endothelin Antagonists Therapeutics in 2026
Figure 74. Manufacturing Process Analysis of Endothelin Antagonists Therapeutics
Figure 75. Industry Chain Structure of Endothelin Antagonists Therapeutics
Figure 76. Channels of Distribution
Figure 77. Global Endothelin Antagonists Therapeutics Sales Market Forecast by Region (2027-2032)
Figure 78. Global Endothelin Antagonists Therapeutics Revenue Market Share Forecast by Region (2027-2032)
Figure 79. Global Endothelin Antagonists Therapeutics Sales Market Share Forecast by Type (2027-2032)
Figure 80. Global Endothelin Antagonists Therapeutics Revenue Market Share Forecast by Type (2027-2032)
Figure 81. Global Endothelin Antagonists Therapeutics Sales Market Share Forecast by Application (2027-2032)
Figure 82. Global Endothelin Antagonists Therapeutics Revenue Market Share Forecast by Application (2027-2032)
